Each soft gelatin capsule contains Saquinavir 200 mg.
Without a Prescription
Saqvir is prescribed for use in combination with other antiretroviral agents for the treatment of HIV infection.
The recommended dose of Saqvir is six 200-mg capsules orally, three times a day (1200 mg t.i.d.). Saqvir should be taken with a meal or up to 2 hours after a meal.
When used in combination with nucleoside analogues, the dosage of Saqvir should not be reduced as this will lead to greater than dose proportional decreases in Saquinavir plasma levels.
Patients should be advised that Saqvir, like other protease inhibitors, is recommended for use in combination with active antiretroviral therapy.
Greater activity has been observed when new antiretroviral therapies are begun at the same time as ritonavir. As with all protease inhibitors, adherence to the prescribed regimen is strongly recommended.
Concomitant therapy should be based on a patientís prior drug exposure.
Saqvir is contraindicated in patients with clinically significant hypersensitivity to saquinavir or to any of the components contained in the capsule.
Saqvir should not be administered concurrently with terfenadine, cisapride, astemizole, triazolam, midazolam or ergot or derivatives, because competition for CYP3A by saquinavir could result in inhibition of the metabolism of these drugs and create the potential for serious and/or life-threatening reactions such as cardiac arrhythmias or prolonged sedation.
- Bottle of 90 capsules;